
|Articles|July 1, 1999
Supplements and Featured Publications
- Evaluating the Health Benefits of Atypical Agents in the Treatment and Management of Psychoses
- Volume 5
- Issue 10 Suppl
CME/CE Quiz
Advertisement
Articles in this issue
over 26 years ago
Participating Facultyover 26 years ago
Introductionover 26 years ago
Assessment of Quality-of-Life Outcomes in Schizophrenic Patientsover 26 years ago
The Emerging Role of Psychiatric Pharmacistsover 26 years ago
Selected Abstractsover 26 years ago
BibliographyNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
2
FDA Approves Ziftomenib for R/R NPM1-Mutated AML
3
Nipocalimab Investigation Extends to Younger Patients: Jonathan Strober, MD
4
Managed Care Reflections: A Q&A With Laurie C. Zephyrin, MD, MPH, MBA
5















































